II.2.2) Cod(au) CPV ychwanegol

85100000

II.2.3) Man cyflawni

Cod NUTS:

UK

II.2.4) Disgrifiad o’r caffaeliad

The key objective of this procurement is to commission Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients. Initially, this will be for the provision of Lifileucel for previously treated unresectable or metastatic melanoma. Services will be commissioned across seven (7) geographical regions to serve the population of England, as outlined below:<br/><br/>Lot 1: London <br/>Lot 2: East of England <br/>Lot 3: South East <br/>Lot 4: South West<br/>Lot 5: Midlands <br/>Lot 6: North East and Yorkshire <br/>Lot 7: North West <br/><br/>Bidders are to note:<br/><br/>- Providers may only bid for one Lot.<br/>- There is no restriction on the number of sites that may be commissioned.<br/>- Providers must be located in and deliver services from the geographical area(s) they are bidding to serve. that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to.<br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams(https://www.england.nhs.uk/about/regional-area-teams/). <br/><br/>The commissioner reserves the right to expand the scope of the contract during its term to include the delivery of additional TIL therapies to treat the same or similar conditions/indications, should they become available and deemed appropriate for inclusion.<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in early 2026.<br/><br/>Link for the current NICE paperwork:<br/>https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>Providers are required to be an established site for the delivery of specialist skin cancer care that complies with the requirements as set out in the current specification, and any future reiterations below: https://www.england.nhs.uk/wp-content/uploads/2018/08/Cancer-skin-adult.pdf<br/><br/>Providers must also;<br/>• Have access to surgical expertise which enables them to perform tumour resections to obtain enough sample tissue for final product to be made. <br/>• Hold the appropriate Human Tissue Authority licences, which includes having the licence to cover the procurement, donor testing and exporting of the resected tissue.<br/>• Have expertise in delivering and managing cellular therapies <br/>• Have experience of managing the adverse effects of interleukin 2 inhibitors. Examples of these adverse events would be those similar to cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.<br/>• Hold a Joint Accreditation Committee of ISCT and EBMT of the European Society for Blood and Marrow Transplantation (JACIE) Immune Effector Cells (IEC) accreditation or be working towards such accreditation with accreditation being in place before contracts are awarded.<br/>• Have experience relevant to Haematopoietic Stem Cell Transplantation. <br/> <br/>Providers must be able to meet the requirements set out in this Competitive Process and deliver the contract in accordance with its terms.<br/><br/>To express interest and participate in the Competitive Process, please register and apply via Atamis esourcing portal https://health-family.force.com/s/Welcome Should Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at:<br/>Phone: 08000988201<br/>E-mail: support-health@atamis.co.uk<br/><br/>The closing date for completed Competitive Process responses is 12:00pm (noon), on Monday 13th October 2025.<br/><br/>Atamis Project reference C385818.<br/><br/>The contract duration is for five (5) years with the Commissioners having the option to extend for up to an additional four (4) year(s) (maximum contract duration nine (9) years).<br/><br/>This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply.

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 142 512 000.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 104

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

The contract duration is for five (5) years with the Commissioners having the option to extend for up to an additional four (4) year(s) (maximum contract duration nine (9) years).

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

NHS Arden and Greater East Midlands Commissioning Support Unit

Cardinal Square, 10 Nottingham Road

Derby

DE1 3QT

UK

Cyfeiriad(au) rhyngrwyd

URL: https://www.ardengemcsu.nhs.uk/